4//SEC Filing
Hamilton James C 4
Accession 0001628280-24-000748
CIK 0000879407other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 8:02 PM ET
Size
20.0 KB
Accession
0001628280-24-000748
Insider Transaction Report
Form 4
Hamilton James C
Chief Medical Officer
Transactions
- Sale
Common Stock
2024-01-05$34.00/sh−1,800$61,200→ 249,134 total - Sale
Common Stock
2024-01-05$35.65/sh−12,343$440,028→ 228,791 total - Sale
Common Stock
2024-01-03$31.81/sh−3,500$111,335→ 178,734 total - Sale
Common Stock
2024-01-03$33.30/sh−500$16,650→ 175,934 total - Award
Common Stock
2024-01-04+75,000→ 250,934 total - Sale
Common Stock
2024-01-05$34.94/sh−8,000$279,520→ 241,134 total - Sale
Common Stock
2024-01-03$32.52/sh−2,300$74,796→ 176,434 total - Sale
Common Stock
2024-01-05$35.00/sh−10,000$350,000→ 218,791 total
Footnotes (11)
- [F1]Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- [F10]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $35.97, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F11]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.06 , inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F2]Partial disposition of RSUs to satisfy tax withholding obligations.
- [F3]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $31.22 to $32.19, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F4]Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
- [F5]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $32.21 to $32.93, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F6]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.69, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F7]Represents shares underlying restricted stock units with a grant date 01/04/24, which will vest in four equal annual installments.
- [F8]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $33.46 to $34.43, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F9]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $34.46 to $35.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Documents
Issuer
ARROWHEAD PHARMACEUTICALS, INC.
CIK 0000879407
Entity typeother
Related Parties
1- filerCIK 0001830755
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 8:02 PM ET
- Size
- 20.0 KB